Table 1.
Preoperative and postoperative variables according to surgical margin status
| Variablesa | NSM group (n = 94) | PSM group (n = 50) | P |
|---|---|---|---|
| Preoperative variables | |||
| Age (yr) | 67.3 (± 6.7) | 64.6 (±6.5) | 0.654 |
| PSA at diagnosis (ng/mL) | 10.5 (± 6.7) | 16.3 (± 11.4) | 0.002 |
| Prostate volume (g) | 35.5 (± 18.6) | 36.4 (± 16.1) | 0.859 |
| GS at diagnosis | 0.225 | ||
| ≤ 6 | 40 (42.5) | 14 (28) | |
| 7 | 37 (39.4) | 24 (48) | |
| ≥ 8 | 17 (18.1) | 12 (24) | |
| Clinical T stage | 0.002 | ||
| ≤ T2 | 84 (89.4) | 34 (68) | |
| > T2 | 10 (10.6) | 16 (32) | |
| CAPRA score risk group | 0.004 | ||
| Low | 39 (41.5) | 9 (18) | |
| Intermediate | 32 (34) | 17 (34) | |
| High | 23 (24.5) | 24 (48) | |
| Postoperative variables | |||
| Postop. PSA (ng/mL) | 0.960 (±0.186) | 0.140 (±0.209) | 0.422 |
| Nadir PSA (ng/mL) Period until nadir PSA (mo) |
0.014 (±0.016) 4.3 (±2.9) |
0.019 (±0.027) 4.2 (±3.2) |
0.007 0.842 |
| Tumor volume (%) | 15.7 (±16.7) | 33.1 (±21.9) | 0.015 |
| No. of biochemical recurrence | 8 (8.5) | 37 (74) | 0.005 |
| Period until BCR (mo) | 32.7 (±20.4) | 35.2 (±22.6) | 0.497 |
BCR, biochemical recurrence; CAPRA, cancer of the prostate risk assessment; GS, Gleason score; NSM, negative surgical margin; PSA, prostate-specific antigen; PSM, positive surgical margin.
a
Variables are presented as mean and standard deviation or number (%).